Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses

Wang,Zhu; Zhang,Jianwen; Zhang,Ying; Deng,Qiong; Liang,Hui

doi:10.3892/ijmm.2018.3870

Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses

Authors:
- Zhu Wang
- Jianwen Zhang
- Ying Zhang
- Qiong Deng
- Hui Liang
View Affiliations

Affiliations: Department of Urology, People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R. China
Published online on: September 11, 2018 https://doi.org/10.3892/ijmm.2018.3870
Pages: 3542-3550

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) are the most well‑known genes linked to breast cancer and ovarian cancer, which are crucial in DNA repair and transcriptional regulation. The present study aimed to elucidate the expression profiles, mutations and interaction networks of BRCA1 and BRCA2, which may provide insights to reveal the mechanisms of BRCA genes ultimately leading to breast or ovarian tumorigenesis. Bioinformatics analyses were performed in the present study. The mRNA levels of BRCA1 and BRCA2 were evaluated using FIREHOSE analysis, SAGE Genie tools and Oncomine analysis. cBioPortal analysis, and Catalogue Of Somatic Mutations In Cancer analysis were used to examine the BRCA1 and BRCA2 mutations. Kaplan‑Meier Plotter analysis was performed to identify the prognostic roles of BRCA1 and BRCA2 in breast cancer and ovarian cancer. The results of the present study showed that the mRNA expression levels of BRCA1 and BRCA2 were elevated in breast cancer and ovarian cancer tissues, compared with their matched normal tissues. Second, several common mutations of BRCA1 and BRCA2 genes were identified in breast cancer and ovarian cancer. Finally, neurofibromin 1, synaptonemal complex protein 2 and tumor protein 53 were predicted to be involved in the interaction network of BRCA1 and BRCA2 in breast cancer and ovarian cancer. Taken together, these results provide a significant insight into certain mutations and proteins involved in the interaction network of BRCA1 and BRCA2, which may have common roles in breast cancer and ovarian cancer. However, the complex mechanism underlying these observations remains to be fully elucidated, and further investigations are required in the future.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 140:2051–2059. 2017. View Article : Google Scholar : PubMed/NCBI
3	Eeles RA: Screening for hereditary cancer and genetic testing, epitomized by breast cancer. Eur J Cancer. 35:1954–1962. 1999. View Article : Google Scholar
4	Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
5	Chapman MS and Verma IM: Transcriptional activation by BRCA1. Nature. 382:678–679. 1996. View Article : Google Scholar : PubMed/NCBI
6	Kolinjivadi AM, Sannino V, de Antoni A, Técher H, Baldi G and Costanzo V: Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51. FEBS Lett. 591:1083–1100. 2017. View Article : Google Scholar : PubMed/NCBI
7	Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM and Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 2:317–328. 1998. View Article : Google Scholar : PubMed/NCBI
8	Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary breast cancer clinical study group Lancet. 356:1876–1881. 2000.
9	Sakorafas GH and Tsiotou AG: Genetic predisposition to breast cancer: A surgical perspective. Br J Surg. 87:149–162. 2000. View Article : Google Scholar : PubMed/NCBI
10	Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G and Monfardini S: BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev. 27:295–304. 2001. View Article : Google Scholar
11	Cicero G, De Luca R, Dorangricchia P, Lo Coco G, Guarnaccia C, Fanale D, Calò V and Russo A: Risk perception and psychological distress in genetic counselling for hereditary breast and/or ovarian cancer. J Genet Couns. 26:999–1007. 2017. View Article : Google Scholar : PubMed/NCBI
12	Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A and Carvallo P: Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival. Bmc Cancer. 16:2192016. View Article : Google Scholar : PubMed/NCBI
13	Ewald IP, Vargas FR, Moreira MA, Filho CM, da Cunha DR, Ramos JP, Ribeiro PL, Caleffi M, Giuglani R and Ashton-Prolla P: Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families. J Clin Oncol. 26:2008. View Article : Google Scholar
14	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBio-Portal. Sci Signal. 6:2013. View Article : Google Scholar
15	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL and Jeffrey SS: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 15:2523–2536. 2004. View Article : Google Scholar : PubMed/NCBI
17	Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
18	Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst. 105:812–822. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chen S and Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 25:1329–1333. 2007. View Article : Google Scholar : PubMed/NCBI
20	Blay P, Santamaria I, Pitiot AS, Luque M, Alvarado MG, Lastra A, Fernández Y, Paredes A, Freije JM and Balbín M: Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 13:2432013. View Article : Google Scholar : PubMed/NCBI
21	Petrucelli N, Daly MB and Feldman GL: Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Mod. 12:245–259. 2010. View Article : Google Scholar
22	Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ and Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004. View Article : Google Scholar : PubMed/NCBI
23	Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kim MC, Choi JE, Lee SJ and Bae YK: Coexistent loss of the expressions of BRCA1 and p53 predicts poor prognosis in triple-negative breast cancer. Ann Surg Oncol. 23:3524–3530. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ju LL, Zhao CY, Ye KF, Yang H and Zhang J: Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Med Pharmacol Sci. 20:1993–2003. 2016.PubMed/NCBI
26	Rajan JV, Wang M, Marquis ST and Chodosh LA: Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA. 93:13078–13083. 1996. View Article : Google Scholar : PubMed/NCBI
27	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
28	Welcsh PL and King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 10:705–713. 2001. View Article : Google Scholar : PubMed/NCBI
29	Parvin S, Islam MS, Al-Mamun MM, Islam MS, Ahmed MU, Kabir ER and Hasnat A: Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. Breast Cancer. 24:229–237. 2016. View Article : Google Scholar : PubMed/NCBI
30	Christou CM and Kyriacou K: BRCA1 and its network of interacting partners. Biology. 2:40–63. 2013. View Article : Google Scholar : PubMed/NCBI
31	Brems H, Beert E, de Ravel T and Legius E: Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 10:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
32	Campos B, Balmaña J, Gardenyes J, Valenzuela I, Abad O, Fàbregas P, Volpini V and Díez O: Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer. Breast Cancer Res Treat. 139:597–602. 2013. View Article : Google Scholar : PubMed/NCBI
33	Madanikia SA, Bergner A, Ye X and Blakeley JO: Increased risk of breast cancer in women with NF1. Am J Med Genet A. 158A:3056–3060. 2012. View Article : Google Scholar : PubMed/NCBI
34	Masterson L, Sorgeloos F, Winder D, Lechner M, Marker A, Malhotra S, Sudhoff H, Jani P, Goon P and Sterling J: Deregulation of SYCP2 predicts early stage human papillomavirus-positive oropharyngeal carcinoma: A prospective whole transcriptome analysis. Cancer Sci. 106:1568–1575. 2015. View Article : Google Scholar : PubMed/NCBI
35	Pannone G, Santoro A, Papagerakis S, Lo Muzio L, De Rosa G and Bufo P: The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: An overview. Infect Agent Cancer. 6:42011. View Article : Google Scholar